NCT00959192 - Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Alzheimer's Disease

Interventions

BIOLOGICAL

ACC-001

IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12

OTHER

QS-21

IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12

OTHER

QS-21

IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12

Trial Locations (9)

Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka

Meitetsu Hospital, Aichi

Ibaraki Prefectural Central Hospital, Ibaraki

Shonan Atsugi Hospital, Kanagawa

Kitasato University East Hospital, Kanagawa

The Jikei University School of medicine, Tokyo

Juntendo University Hospital, Tokyo

Juntendo Tokyo Koto Geriatric Medical Center, Tokyo

Kanto Ctrl Hp of the Mutual Aid Asso of Public school Teache, Tokyo